Seoul (1)

Hematologic Maligmancy (1)

Active, not recruiting (1)

Pfizer (1)

inotuzumab ozogamicin (1)

drug (1)

Industry (1)

Observational (1)

hematologic maligmancy

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Oct 10, 2022